Stoke Therapeutics Inc. (NASDAQ: STOK) Making Surprising Moves in Wednesday Session

May 15, 2024 11:21:57

Stoke Therapeutics, Inc. (NASDAQ: STOK) has caught the attention of the investment community today with its bullish price action. The company’s shares have moved 11.25% on the day to $14.24.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy.

So far today, approximately 580.25k shares of Stoke Therapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 702.56k shares.

Stoke Therapeutics, Inc. share prices have moved between a 52-week high of $16.4 and a 52-week low of $3.35. The stock has moved 6.58% over the past week.

To learn more about Stoke Therapeutics, Inc., visit the company’s website at

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit

About IBN

IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

Los Angeles, California
310.299.1717 Office